Spark will continue its operations in Philadelphia as an independent company within the Roche Group Basel, 17 December 2019 – Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced the completion of the acquisition following the receipt of regulatory approval from all government authorities required by the merger agreement. Commenting... Read more
Nearly 80% of US and UK health professionals say AI has reduced health worker burnout;45% say it has increased time to consult with and treat patients CHICAGO and LONDON – DECEMBER 16, 2019 – Artificial Intelligence (AI) is widely expected to drive important benefits across the health system, from increasing efficiency to improving patient outcomes,... Read more
Roche intends to complete Spark acquisition today Basel, 17 December 2019 – Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that Roche’s wholly owned subsidiary 022019 Merger Subsidiary, Inc. has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all... Read more
All antitrust approvals required to close the transaction received. Basel, 16 December 2019 – Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that the Federal Trade Commission closed its investigation and granted unconditional clearance and termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976... Read more
Basel, 16 December 2019 – Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that the UK Competition and Markets Authority has unconditionally cleared Roche’s pending acquisition of Spark pursuant to its previously announced tender offer to purchase all of the outstanding shares of common stock (the “Shares”) of... Read more
Basel, 09 December 2019 Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. to December 16, 2019 Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that Roche has extended the offering period of its previously announced tender offer to purchase all... Read more
Fujifilm Establishes the Bio Science & Engineering Laboratories U.S.A. to Start Full-scale Translational Research for Biotherapeutics in the United States – Fujifilm Cellular Dynamics Usage of Cookies: Cookies are important to the proper functioning of this site. To improve your experience, we use cookies to remember log-in details and provide secure log-in, collect statistics to... Read more
Agilent Companion Diagnostic Expands CE-IVD mark in Europe to include Head and Neck Squamous Cell Carcinoma (HNSCC) PD-L1 IHC 22C3 pharmDx can now be used as an aid in identifying HNSCC patients for treatment with KEYTRUDA® (pembrolizumab) in Europe SANTA CLARA, Calif., November 22, 2019 Agilent Technologies, Inc. (NYSE: A) today announced that its PD-L1... Read more
Basel, 22 November 2019 Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that Roche has extended the offering period of its previously announced tender offer to purchase all of the outstanding shares... Read more
Agilent Announces New ICP-OES Systems with Innovative Instrument Intelligence Smart capabilities deliver deep insight into samples, processes, and operational status SANTA CLARA, Calif., November 19, 2019 Agilent Technologies, Inc. (NYSE: A) today announced a new generation of ICP-OES systems for laboratories serving the environmental, food, energy, chemicals, and materials markets. The new Agilent 5800 ICP-OES... Read more